Onderneming SYNLAB AG Deutsche Boerse AG
Aandelen
SYAB
DE000A2TSL71
Gezondheidszorgvoorzieningen & -diensten
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
10,85 EUR | +0,18% | -1,36% | -4,91% |
25/03 | Dpa-AFX Overzicht: BEDRIJVEN van 25/03/2024 - 15:15 | DP |
25/03 | Transcript : SYNLAB AG, 2023 Earnings Call, Mar 25, 2024 |
Vakgebied
Aantal werknemers: 23 538
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Human Medicine
97,6
%
| 3 168 | 97,5 % | 2 572 | 97,6 % | -18,79% |
Veterinary Medicine
1,1
%
| 42 | 1,3 % | 29 | 1,1 % | -29,98% |
Trading Goods and Services
0,7
%
| 20 | 0,6 % | 20 | 0,7 % | -1,03% |
Environmental and Other Analysis, Studies, Expertise
0,3
%
| 10 | 0,3 % | 9 | 0,3 % | -10,26% |
Software Solutions and Services
0,2
%
| 12 | 0,4 % | 6 | 0,2 % | -53,57% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Germany
20,3
%
| 703 | 21,6 % | 536 | 20,3 % | -23,75% |
France
19,9
%
| 674 | 20,7 % | 524 | 19,9 % | -22,24% |
South
17,5
%
| 0 | 0,0 % | 461 | 17,5 % | - |
Italy
13,0
%
| 355 | 10,9 % | 343 | 13,0 % | -3,59% |
United Kingdom
13,0
%
| - | - | 343 | 13,0 % | - |
North & East
8,3
%
| 913 | 28,1 % | 217 | 8,3 % | -76,17% |
Latin America
8,0
%
| 192 | 5,9 % | 211 | 8,0 % | +9,76% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 56 | 26-01-21 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 26-01-21 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 40 | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Mark Reinhard
IRC | Investor Relations Contact | - | 01-01-21 |
Walla Fabian
SEC | Corporate Secretary | - | - |
Human Resources Officer | - | - | |
Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 11-01-21 |
Founder | 63 | 01-01-98 | |
Marc Welters
BRD | Director/Board Member | - | 29-04-21 |
Director/Board Member | 50 | 29-04-21 | |
Barbara Lambert
BRD | Director/Board Member | 62 | 11-01-21 |
Karin Bierstedt
BRD | Director/Board Member | 52 | 29-04-21 |
Stefan Graf
BRD | Director/Board Member | 65 | 29-04-21 |
Ute Hasholzner
BRD | Director/Board Member | 65 | 29-04-21 |
Director/Board Member | 62 | 29-04-21 | |
Iris Schopper
BRD | Director/Board Member | 36 | 29-04-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 222 222 222 | 76 278 423 ( 34,33 %) | 2 447 000 ( 1,101 %) | 34,33 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
SYNLAB AG 1.13% | 2 518 864 | 1.13% | 33 881 542 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
SYNLAB Bondco Plc
SYNLAB Bondco Plc Financial ConglomeratesFinance SYNLAB Bondco Plc offers medical diagnostics for patients, practicing doctors, clinics and the pharmaceutical industry. The company was founded on March 23, 2015 and is headquartered in London, the United Kingdom. |
Financial Conglomerates
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-8,32% | 9,21 mld. | |
-9,54% | 3,67 mld. | |
+39,95% | 3,59 mld. | |
-12,21% | 2,25 mld. | |
-2,84% | 2,01 mld. | |
-16,85% | 1,63 mld. | |
-25,37% | 1,54 mld. | |
-7,98% | 1,12 mld. | |
+2,71% | 1,06 mld. |
- Beurs
- Aandelen
- Aandeel SYNLAB AG
- Aandeel SYNLAB AG - Deutsche Boerse AG
- Onderneming SYNLAB AG